Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
R406
Description:
Tamatinib is a small-molecule inhibitor of spleen tyrosine kinase studied in biomedical research on immune signaling and disease.
Related topics:
Chronic Lymphocytic Leukemia Research (10%),
Lymphoma Diagnosis and Treatment (7%),
Rheumatoid Arthritis Research and Therapies (7%)
Wikidata ID:
wiki/Q27088935
OpenAlex ID:
keywords/r406
R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation
2006
·
Sylvia Braselmann
, Vanessa Taylor
, et al.
·
Journal of Pharmacology and Experimental Therapeutics
·
541
Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve‐week, randomized, placebo‐controlled trial
2008
·
Michael E. Weinblatt
, Arthur Kavanaugh
, et al.
·
Arthritis & Rheumatism
·
358
Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk
2008
·
Anna Podolanczuk
, Alan H. Lazarus
, et al.
·
Blood
·
276
B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406
2009
·
Maite P. Quiroga
, Kumudha Balakrishnan
, et al.
·
Blood
·
265
Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells
2008
·
S Gobessi
, L Laurenti
, et al.
·
Leukemia
·
230
Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor
2007
·
Polly R. Pine
, Betty Chang
, et al.
·
Clinical Immunology
·
220
Spleen Tyrosine Kinase Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia
2009
·
Maike Buchner
, Simon Fuchs
, et al.
·
Cancer Research
·
206
Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia
2010
·
Maike Buchner
, Constance Baer
, et al.
·
Blood
·
194
Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase
2014
·
Kevin S. Currie
, Jeffrey E. Kropf
, et al.
·
Journal of Medicinal Chemistry
·
184
A Novel Spleen Tyrosine Kinase Inhibitor Blocks c-Jun N-Terminal Kinase-Mediated Gene Expression in Synoviocytes
2006
·
Hoon-Suk Cha
, David L. Boyle
, et al.
·
Journal of Pharmacology and Experimental Therapeutics
·
145
The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC‐2 signaling in platelets
2009
·
J.C. SPALTON
, J. MORI
, et al.
·
Journal of Thrombosis and Haemostasis
·
135
PDF
BCR signaling inhibitors differ in their ability to overcome Mcl-1–mediated resistance of CLL B cells to ABT-199
2016
·
Kamil Bojarczuk
, Binu K. Sasi
, et al.
·
Blood
·
134
PDF
In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib
2015
·
Michael G. Rolf
, Jon O. Curwen
, et al.
·
Pharmacology Research & Perspectives
·
112
PDF
Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic
2020
·
Jeffrey R Strich
, Marcos J Ramos-Benitez
, et al.
·
The Journal of Infectious Diseases
·
111
PDF
Inhibition of Spleen Tyrosine Kinase Prevents Mast Cell Activation and Airway Hyperresponsiveness
2005
·
Shigeki Matsubara
, Guiming Li
, et al.
·
American Journal of Respiratory and Critical Care Medicine
·
109
Metabolism of Fostamatinib, the Oral Methylene Phosphate Prodrug of the Spleen Tyrosine Kinase Inhibitor R406 in Humans: Contribution of Hepatic and Gut Bacterial Processes to the Overall Biotransformation
2010
·
David J. Sweeny
, Weiqun Li
, et al.
·
Drug Metabolism and Disposition
·
97
Deregulated Syk inhibits differentiation and induces growth factor–independent proliferation of pre–B cells
2006
·
Thomas Wossning
, Sebastian Herzog
, et al.
·
The Journal of Experimental Medicine
·
90
PDF
Syk Activation in Dendritic Cells Is Essential for Airway Hyperresponsiveness and Inflammation
2005
·
Shigeki Matsubara
, Toshiyuki Koya
, et al.
·
American Journal of Respiratory Cell and Molecular Biology
·
89
A Spleen Tyrosine Kinase Inhibitor Reduces the Severity of Established Glomerulonephritis
2009
·
Jennifer Smith
, John P. McDaid
, et al.
·
Journal of the American Society of Nephrology
·
87
Costimulation of Dectin-1 and DC-SIGN Triggers the Arachidonic Acid Cascade in Human Monocyte-Derived Dendritic Cells
2008
·
Isela Valera
, Nieves Fernández
, et al.
·
The Journal of Immunology
·
78
Toxoplasma gondii activates a Syk-CARD9-NF-κB signaling axis and gasdermin D-independent release of IL-1β during infection of primary human monocytes
2019
·
William J. Pandori
, Tatiane S. Lima
, et al.
·
PLoS Pathogens
·
76
PDF
FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas
2016
·
Maciej Szydlowski
, Przemyslaw Kiliszek
, et al.
·
Blood
·
72
A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury
2020
·
Maria Kost-Alimova
, Eriene-Heidi Sidhom
, et al.
·
Cell Reports Medicine
·
71
PDF
Structural Insights for Design of Potent Spleen Tyrosine Kinase Inhibitors from Crystallographic Analysis of Three Inhibitor Complexes
2009
·
Armando G. Villaseñor
, Rama Kondru
, et al.
·
Chemical Biology & Drug Design
·
69
Therapeutic inhibition of spleen tyrosine kinase in inflammatory macrophages using PLGA nanoparticles for the treatment of non-alcoholic steatohepatitis
2018
·
Dhadhang Wahyu Kurniawan
, Arun Kumar Jajoriya
, et al.
·
Journal of Controlled Release
·
68
PDF
Show more works
View as search
Works count:
228
Citation count:
6,545
Year
Topic
Type